MedPacto Obtains Domestic Patent Rights Related to 'BAG2 Antibody'
[Asia Economy Reporter Kum Boryeong] MedPacto announced on the 27th that it has acquired a domestic patent related to 'Composition for cancer diagnosis using BAG2 antibody and method thereof.'
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
MedPacto stated, "Our company is developing a diagnostic kit (MO-B2) aimed at diagnosing cancer metastasis and recurrence using BAG2, which we discovered for the first time in the world as a biomarker," adding, "We signed a contract with Thermo Fisher Scientific in early August to conduct research for commercialization and production of the diagnostic kit."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
